Pancreatic Cancer Research

ResearcherRoyal Marsden NHS Foundation TrustActive in the last 2 years

Katharine L. Aitken

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2942-3678; OpenAlex author ID A5058395730. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 9

  1. Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre Experience. Last author DOI 10.3390/cancers18101597↗
  2. Complete Primary Pathological Response Following Neoadjuvant Treatment and Radical Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16020452↗
  3. Stereotactic Ablative Body Radiotherapy for Locally Advanced Unresectable Pancreatic Cancer: Current Views of the Public and Professionals. Co-author DOI 10.1016/j.clon.2020.10.015↗
  4. Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". Co-author DOI 10.1038/s41416-020-01133-8↗
  5. Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Co-author DOI 10.3389/fonc.2021.628155↗
  6. Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Co-author DOI 10.1016/j.prro.2020.01.012↗
  7. Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. Co-author DOI 10.1038/s41416-020-0980-x↗
  8. Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer. Last author DOI 10.1016/j.ctro.2019.03.001↗
  9. Recommendations for MRI-based contouring of gross tumor volume and organs at risk for radiation therapy of pancreatic cancer. Co-author DOI 10.1016/j.prro.2016.10.006↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ricky Harminder Bhogal · 2 shared papers, 2024–2026 · strength 0.46
  2. Kai Tai Derek Yeung · 2 shared papers, 2024–2026 · strength 0.46
  3. David Cunningham · 2 shared papers, 2024–2026 · strength 0.46
  4. Ganesh Radhakrishna · 3 shared papers, 2020–2021 · strength 0.33
  5. Somnath Mukherjee · 3 shared papers, 2020–2021 · strength 0.33
  6. Bradley A. Erickson · 3 shared papers, 2017–2021 · strength 0.27
  7. William Adrian Hall · 3 shared papers, 2017–2021 · strength 0.27
  8. Eugene Jon Koay · 3 shared papers, 2017–2021 · strength 0.27
  9. Christopher H. Crane · 3 shared papers, 2017–2021 · strength 0.27
  10. Naureen Starling · 1 shared paper, 2026 · strength 0.24
  11. Ian Chau · 1 shared paper, 2026 · strength 0.24
  12. Long R. Jiao · 1 shared paper, 2024 · strength 0.23
  13. Sten D. Myrehaug · 2 shared papers, 2020–2021 · strength 0.21
  14. Laura Ann Dawson · 2 shared papers, 2020–2021 · strength 0.21
  15. James S. Good · 2 shared papers, 2020–2021 · strength 0.19
  16. Paula Ghaneh · 2 shared papers, 2020–2021 · strength 0.19
  17. Derek B. Grose · 2 shared papers, 2020–2021 · strength 0.19
  18. Christopher Mark Jones · 2 shared papers, 2020–2021 · strength 0.19
  19. Daniel H. Palmer · 2 shared papers, 2020–2021 · strength 0.19
  20. D. Holyoake · 2 shared papers, 2020–2021 · strength 0.19
  21. M. Hawkins · 2 shared papers, 2020–2021 · strength 0.19
  22. Nigel Balfour Jamieson · 2 shared papers, 2020–2021 · strength 0.19
  23. Juan W. Valle · 2 shared papers, 2020–2021 · strength 0.19
  24. Pippa G. Corrie · 2 shared papers, 2020–2021 · strength 0.19
  25. Hanne D. Heerkens · 2 shared papers, 2017–2021 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.